Checkpoint Therapeutics (CKPT) has agreed to be acquired by India's Sun Pharmaceutical Industries for $4.10 per share in cash plus a non-transferable contingent value right, the companies said Sunday.
The contingent value right entitles the stockholder to receive up to an additional $0.70 in cash if metastatic cutaneous squamous cell carcinoma treatment cosibelimab is approved before deadlines in the European Union or in certain countries, the companies said.
Checkpoint, its controlling shareholder Fortress Biotech (FBIO), and Sun Pharma have also entered into a royalty agreement under which Fortress will receive royalties from future sales of cosibelimab during a specified term.
The proposed transaction is expected to close in Q2, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.